Platelet activation, soluble Nox2-derivated peptide, and oxidised LDL were monitored in patients with familial hypercholesterolemia before, and after, treatment with PCSK9 inhibitors. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.